TLR3 expression on tumor cells elicited favorable NSCLC outcomes during early stages, whereas TLR3 expression on immune cells, primarily macrophages, elicited poor prognosis in patients’ survival (53). This evidence concerns the gene TLR3 and non-small cell lung carcinoma.